The Kidney Disease: Improving Global Outcomes (KDIGO) 2021 guidelines for the management of glomerular diseases indicate that treatment and monitoring of patients with PMN depend on the baseline risk of progression, which is mainly based on proteinuria, kidney function and anti-PLA2R antibodies [1]. This evidence concerns the gene PLA2R1 and glomerular disorder.